Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Receivables (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Change in Receivables for 10 consecutive years, with $614000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 94.09% year-over-year to $614000.0, compared with a TTM value of $5.9 million through Dec 2025, down 69.92%, and an annual FY2025 reading of $5.9 million, down 69.92% over the prior year.
  • Change in Receivables was $614000.0 for Q4 2025 at Amicus Therapeutics, down from $8.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $12.5 million in Q2 2025 and bottomed at -$15.3 million in Q1 2025.
  • Average Change in Receivables over 5 years is $3.5 million, with a median of $3.3 million recorded in 2021.
  • The sharpest move saw Change in Receivables soared 610.07% in 2021, then tumbled 799.12% in 2024.
  • Year by year, Change in Receivables stood at $1.8 million in 2021, then skyrocketed by 445.07% to $9.9 million in 2022, then grew by 16.05% to $11.5 million in 2023, then fell by 9.57% to $10.4 million in 2024, then plummeted by 94.09% to $614000.0 in 2025.
  • Business Quant data shows Change in Receivables for FOLD at $614000.0 in Q4 2025, $8.1 million in Q3 2025, and $12.5 million in Q2 2025.